Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 893243, 8 pages
http://dx.doi.org/10.1155/2014/893243
Research Article

Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma

1Department of Laboratory Medicine, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 410-769, Republic of Korea
2Hematologic-Oncology Clinic, Center for Specific Organs Cancer, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 410-769, Republic of Korea
3Hematologic Malignancy Branch, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea
4Translational Epidemiology Research Branch, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea

Received 21 February 2014; Revised 28 April 2014; Accepted 8 May 2014; Published 4 June 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Hyoeun Shim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. E. Craig and K. A. Foon, “Flow cytometric immunophenotyping for hematologic neoplasms,” Blood, vol. 111, no. 8, pp. 3941–3967, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Paiva, J. Almeida, M. Perez-Andres et al., “Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders,” Cytometry B: Clinical Cytometry, vol. 78, no. 4, pp. 239–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Bataille, G. Jego, N. Robillard et al., “The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy,” Haematologica, vol. 91, no. 9, pp. 1234–1240, 2006. View at Google Scholar · View at Scopus
  4. W. Eisterer, O. Bechter, W. Hilbe et al., “CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma,” Leukemia Research, vol. 25, no. 12, pp. 1051–1057, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Pellat-Deceunynck, S. Barille, G. Jego et al., “The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma,” Leukemia, vol. 12, no. 12, pp. 1977–1982, 1998. View at Google Scholar · View at Scopus
  6. N. Robillard, C. Pellat-Deceunynck, and R. Bataille, “Phenotypic characterization of the human myeloma cell growth fraction,” Blood, vol. 105, no. 12, pp. 4845–4848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. N. J. Bahlis, A. M. King, D. Kolonias et al., “CD28-mediated regulation of multiple myeloma cell proliferation and survival,” Blood, vol. 109, no. 11, pp. 5002–5010, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. U. Cho, C. J. Park, S. J. Park et al., “Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients,” Journal of Korean Medical Science, vol. 28, no. 4, pp. 542–549, 2013. View at Publisher · View at Google Scholar
  9. G. Mateo, M. A. Montalban, M.-B. Vidriales et al., “Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2737–2744, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. H. E. Johnsen, M. Bogsted, T. W. Klausen et al., “Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma,” Cytometry B: Clinical Cytometry, vol. 78, no. 5, pp. 338–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. Kyle and S. V. Rajkumar, “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma,” Leukemia, vol. 23, no. 1, pp. 3–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. B. G. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival,” Cancer, vol. 36, no. 3, pp. 842–854, 1975. View at Google Scholar · View at Scopus
  13. P. R. Greipp, J. S. Miguel, B. G. Dune et al., “International staging system for multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3412–3420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. B. G. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Publisher · View at Google Scholar
  15. W. J. Chng, A. Dispenzieri, C. S. Chim et al., “IMWG consensus on risk stratification in multiple myeloma,” Leukemia, vol. 28, no. 2, pp. 269–277, 2014. View at Google Scholar
  16. N. Sahara, K. Ohnishi, T. Ono et al., “Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma,” European Journal of Haematology, vol. 77, no. 1, pp. 14–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Robillard, S. Wuilleme, L. Lode, F. Magrangeas, S. Minvielle, and H. Avet-Loiseau, “CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target,” Leukemia, vol. 19, no. 11, pp. 2021–2022, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Riemann, A. Kehlen, and J. Langner, “CD13—not just a marker in leukemia typing,” Immunology Today, vol. 20, no. 2, pp. 83–88, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. D. Freeman, S. Kelm, E. K. Barber, and P. R. Crocker, “Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules,” Blood, vol. 85, no. 8, pp. 2005–2012, 1995. View at Google Scholar · View at Scopus
  20. S. P. Paul, L. S. Taylor, E. K. Stansbury, and D. W. McVicar, “Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2,” Blood, vol. 96, no. 2, pp. 483–490, 2000. View at Google Scholar · View at Scopus
  21. Y.-W. Chang, S.-C. Chen, E.-C. Cheng et al., “CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells,” International Journal of Cancer, vol. 116, no. 2, pp. 243–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. P. R. Greipp, N. M. Raymond, R. A. Kyle, and W. M. O'Fallon, “Multiple myeloma: significance of plasmablastic subtype in morphological classification,” Blood, vol. 65, no. 2, pp. 305–310, 1985. View at Google Scholar · View at Scopus
  23. A. Carter, I. Hocherman, S. Linn, Y. Cohen, and I. Tatarsky, “Prognostic significance of plasma cell morphology in multiple myeloma,” Cancer, vol. 60, no. 5, pp. 1060–1065, 1987. View at Google Scholar · View at Scopus
  24. R. Subramanian, D. Basu, and T. K. Dutta, “Prognostic significance of bone marrow histology in multiple myeloma,” Indian Journal of Cancer, vol. 46, no. 1, pp. 40–45, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Drach, C. Gattringer, and H. Huber, “Expression of the neural cell adhesion molecule (CD56) by human myeloma cells,” Clinical and Experimental Immunology, vol. 83, no. 3, pp. 418–422, 1991. View at Google Scholar · View at Scopus
  26. N. Robillard, H. Avet-Loiseau, R. Garand et al., “CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma,” Blood, vol. 102, no. 3, pp. 1070–1071, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Harrington, P. Hari, and S. H. Kroft, “Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma,” American Journal of Clinical Pathology, vol. 132, no. 1, pp. 60–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Schmidt-Hieber, M. Perez-Andres, B. Paiva et al., “CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features,” Haematologica, vol. 96, no. 2, pp. 328–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Ocqueteau, A. Orfao, R. Garcia-Sanz, J. Almeida, M. Gonzalez, and J. F. S. Miguel, “Expression of the CD117 antigen (C-Kit) on normal and myelomatous plasma cells,” British Journal of Haematology, vol. 95, no. 3, pp. 489–493, 1996. View at Publisher · View at Google Scholar
  30. M. Kraj, R. Poglod, J. Kopec-Szlezak, U. Sokolowska, J. Wozniak, and B. Kruk, “C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies,” Leukemia and Lymphoma, vol. 45, no. 11, pp. 2281–2289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Pruneri, M. Ponzoni, A. J. M. Ferreri et al., “The prevalence and clinical implications of c-kit expression in plasma cell myeloma,” Histopathology, vol. 48, no. 5, pp. 529–535, 2006. View at Publisher · View at Google Scholar · View at Scopus